Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant
Loading...
Official URL
Full text at PDC
Publication date
2021
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Citations
Exportar
Citation
Fernández, L., Solana, J. C., Sánchez, C., Jiménez, M. Á., Requena, J. M., Coler, R., Reed, S. G., Valenzuela, J. G., Kamhawi, S., Oliveira, F., Fichera, E., Glueck, R., Bottazzi, M. E., Gupta, G., Cecilio, P., Pérez-Cabezas, B., Cordeiro-da-Silva, A., Gradoni, L., Carrillo, E., & Moreno, J. (2021). Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant. Microorganisms, 9(11), 2253. https://doi.org/10.3390/microorganisms9112253
Abstract
Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work examines the efficacy of a novel vaccine consisting of the Leishmania membrane protein KMP11, LEISH-F3+ (a recombinant fusion protein, composed of epitopes of the parasite proteins nucleoside hydrolase, sterol-24-c-methyltransferase, and cysteine protease B), and the sand fly salivary protein LJL143, in two dose ratios. The inclusion of the TLR4 agonist GLA-SE as an adjuvant, and the use of virosomes (VS) as a delivery system, are also examined. In a hamster model of VL, the vaccine elicited antigen-specific immune responses prior to infection with Leishmania infantum. Of note, the responses were greater when higher doses of KMP11 and LEISH-F3+ proteins were administered along with the GLA-SE adjuvant and/or when delivered within VS. Remarkably, hamsters immunized with the complete combination (i.e., all antigens in VS + GLA-SE) showed significantly lower parasite burdens in the spleen compared to those in control animals. This protection was underpinned by a more intense, specific humoral response against the KMP11, LEISH-F3+, and LJL143 antigens in vaccinated animals, but a significantly less intense antibody response to the pool of soluble Leishmania antigens (SLA). Overall, these results indicate that this innovative vaccine formulation confers protection against L. infantum infection, supporting the advancement of the vaccine formulation into process development and manufacturing and the conduction of toxicity studies towards future phase I human clinical trials.
Description
Author Contributions
Conceptualization, J.M.; methodology, C.S. and L.F.; software, L.F., J.C.S., M.Á.J. and E.C.; validation, E.C. and J.M.; formal analysis, L.F., J.C.S., M.Á.J. and E.C.; investigation, L.F. and C.S.; resources, J.M.; data curation, L.F., J.C.S., M.Á.J. and E.C.; writing—original draft preparation, J.C.S., M.Á.J. and E.C.; writing—review and editing, J.M.R., R.C., S.G.R., J.G.V., S.K., F.O., E.F., R.G., M.E.B., G.G., P.C., B.P.-C., A.C.-d.-S., L.G., E.C. and J.M.; visualization, J.M.; supervision, J.M.; project administration, J.M.; funding acquisition, J.M. Author Reinhard Glueck was unable to confirm their authorship contributions. On their behalf, the corresponding author has reported their contributions to the best of their knowledge. All authors have read and agreed to the published version of the manuscript.